We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
+$45.6M
Cap. Flow
+$18.2M
Cap. Flow %
6.78%
Top 10 Hldgs %
33.7%
Holding
508
New
146
Increased
78
Reduced
73
Closed
186

Top Buys

1
TSEM icon
Tower Semiconductor
TSEM
+$9.09M
2
LITE icon
Lumentum
LITE
+$8.24M
3
GLW icon
Corning
GLW
+$6.49M
4
INTC icon
Intel
INTC
+$5.94M
5
ALAB icon
Astera Labs
ALAB
+$4.77M

Top Sells

1
CNC icon
Centene
CNC
+$9.07M
2
MOH icon
Molina Healthcare
MOH
+$8.9M
3
ELV icon
Elevance Health
ELV
+$8.08M
4
BTSG icon
BrightSpring Health Services
BTSG
+$3.52M
5
TERN
Terns Pharmaceuticals
TERN
+$2.78M

Sector Composition

1 Technology 44.62%
2 Healthcare 29.67%
3 Financials 9.04%
4 Consumer Discretionary 3.92%
5 Energy 3.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
226
CALL
Biohaven
BHVN
$2.32B
$132K 0.05%
806
+270
+50% +$2.95K
ANTX icon
227
AN2 Therapeutics
ANTX
$169M
$130K 0.05%
+38,155
New +$78.7K
QURE icon
228
uniQure
QURE
$2.77B
$129K 0.05%
7,887
-3,127
-28% -$63.3K
PTHS
229
Pelthos Therapeutics
PTHS
$93.8M
$126K 0.05%
6,007
– –
MKSI icon
230
MKS Inc
MKSI
$21.9B
$120K 0.04%
+520
New +$118K
AVTX icon
231
Avalo Therapeutics
AVTX
$1.02B
$118K 0.04%
7,918
-7,169
-48% -$112K
MNKD icon
232
MannKind Corp
MNKD
$1.25B
$116K 0.04%
47,394
-34,069
-42% -$152K
QURE icon
233
CALL
uniQure
QURE
$2.77B
$114K 0.04%
+640
New +$13K
LPCN icon
234
Lipocine
LPCN
$18.4M
$107K 0.04%
13,442
-57,134
-81% -$498K
URGN icon
235
UroGen Pharma
URGN
$1.96B
$105K 0.04%
5,824
-6,982
-55% -$140K
SLB icon
236
SLB Ltd
SLB
$70.3B
$103K 0.04%
2,000
-8,000
-80% -$388K
CORT icon
237
Corcept Therapeutics
CORT
$9.72B
$102K 0.04%
2,528
-23,304
-90% -$871K
IBRX icon
238
PUT
ImmunityBio
IBRX
$8.04B
$98.6K 0.04%
+270
New +$1.85K
COIN icon
239
PUT
Coinbase
COIN
$41.4B
$96.6K 0.04%
+47
New +$9.25K
GHRS icon
240
GH Research
GHRS
$1.97B
$95.5K 0.04%
+6,794
New +$104K
REPL icon
241
CALL
Replimune Group
REPL
$859M
$94.1K 0.04%
+520
New +$3.98K
ADPT icon
242
Adaptive Biotechnologies
ADPT
$3.67B
$92.8K 0.03%
6,689
– –
OCGN icon
243
Ocugen
OCGN
$460M
$91.5K 0.03%
+50,559
New +$87.4K
RVMD icon
244
PUT
Revolution Medicines
RVMD
$39.6B
$90.5K 0.03%
+317
New +$32K
CRBP icon
245
CALL
Corbus Pharmaceuticals
CRBP
$167M
$85.6K 0.03%
+292
New +$2.46K
CYTK icon
246
PUT
Cytokinetics
CYTK
$10.9B
$84.8K 0.03%
+506
New +$32.2K
CORT icon
247
CALL
Corcept Therapeutics
CORT
$9.72B
$83.9K 0.03%
+401
New +$15K
IRD
248
Opus Genetics
IRD
$270M
$81.5K 0.03%
+17,919
New +$62K
APO icon
249
CALL
Apollo Global Management
APO
$69.5B
$75.1K 0.03%
+304
New +$37.7K
PRQR icon
250
ProQR Therapeutics
PRQR
$240M
$74.6K 0.03%
46,067
+913
+2% +$1.5K
8 9
10
11 12

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Persistent Asset Partners held 508 positions worth $268M, up 20% from $223M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Persistent Asset Partners deployed $18.2M of net new capital in Q1 2026, opening 146 new positions and adding to 78 existing holdings. Its largest new stake was Tower Semiconductor: 67,608 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.78M trimmed.

  • Persistent Asset Partners's largest Q1 2026 buy was Tower Semiconductor: 67,608 shares worth $11.9M.
  • Persistent Asset Partners added most to Lumentum in Q1 2026, an estimated $8.24M increase.
  • Persistent Asset Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $2.78M.
  • Persistent Asset Partners fully exited Centene in Q1 2026, selling an estimated $9.07M.
  • Persistent Asset Partners's ten largest holdings make up 34% of its $268M portfolio in Q1 2026.
  • Persistent Asset Partners opened 146 new positions and closed 186 in Q1 2026.
  • Persistent Asset Partners's portfolio value rose 20% quarter-over-quarter to $268M.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.